Fangda Partners boosts its biopharmacy and aircraft leasing practices in China

Fangda Partners boosts its biopharmacy and aircraft leasing practices in China

Fangda Partners has hired Henry He and Judy Tan as partners to expand the firm's biopharmaceutical and aircraft leasing businesses. Henry He, based in Shanghai, was a board secretary and head of legal at CStone Pharmaceuticals and specialises in life sciences and healthcare, including technology licensing, asset acquisitions, and divestitures, drug discovery collaborations, and option trading. Tan is based in Guangzhou.

Henry He has advised on over 15 cross-border licensing and co-development transactions with global pharmaceutical companies in his 5 years in-house, including representing CStone Pharmaceuticals in a USD 1.15 billion global out-licensing partnership with EQRx for two key immune checkpoint inhibitors. He has also worked with companies such as Pfizer, LegoChem Biosciences, Hengrui Medicine, and Blueprint Medicines, among others.

Before joining CStone Pharmaceuticals, Henry practised at Cooley and Baker McKenzie and is qualified in the PRC and Massachusetts.

Judy Tan, a banking and financing specialist, has over two decades of experience in the aviation sector and is proficient in the purchase, disposal, financing, and leasing of various aircraft, including Boeing, Airbus, and Bombardier planes, business jets, and helicopters. She advised Natixis on a USD 500 million 30-aircraft leasing project with ICBC Aviation Leasing in 2018, handling matters related to French lease taxes and China's bonded area.

Tan worked at the US law firm Condon & Forsyth in 2000 and then moved to Hong Kong in 2003 where she worked at Norton Rose Fulbright, Allen & Overy, and William KK Ho & Ko. She was later a partner at JunZeJun Law Offices before joining Fangda Partners.